Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3972316 | 0.98 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2AMEN1GAACDC7 | |
| SCHEMBL1433150 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2AMEN1GAACDC7 | |
| Methane SCHEMBL11679474 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AMEN1GAACDC7 | |
| Hydrochloric Acid SCHEMBL28669566 | 0.82 | ADORA3 (0.38) | SMN1; SMN2GAARAB9ATSHRADORA3 | |
| SCHEMBL11680658 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AMEN1GAACDC7 | |
| SCHEMBL3243742 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2KMT2AMEN1GAARAB9A | |
| SCHEMBL5390729 | 0.76 | KMT2A (0.40) | SMN1; SMN2KMT2AMEN1GAACDC7 | |
| Hydrochloric Acid SCHEMBL5966969 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2KMT2AMEN1GAARAB9A | |
| SCHEMBL26670579 | 0.76 | SMN1; SMN2 (0.35) | SMN1; SMN2KMT2AMEN1GAARAB9A | |
| SCHEMBL12862672 | 0.76 | NLRP3 (0.41) | SMN1; SMN2KMT2AMEN1GAACDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591341-B2 | Bicyclic and tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20200361947-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2020214728-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-9540394-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-7056903-B2 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | COURNOYER RICHARD L | 2006-02-16 | — | — | US | disclosed |
| CN-1241909-C | Carboxylic acid derivatives as IP antagonists | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
| US-20050277628-A1 | Substituted thiophene carboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| US-6693098-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIVES CONTAINING CARBAMATE GROUPS ARE USEFUL FOR TREATING THE CONDITIONS ASSOCIATED WITH THE URINARY TRACT, PAIN, INFLAMMATION, RESPIRATORY STATES, EDEMA FORMATION OF HYPOTENSIVE VASCULAR DISEASES | SYNTEX (U.S.A) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | COURNOYER RICHARD LEO (US) | 2003-11-27 | — | — | US | disclosed |
| CN-1418187-A | Carboxylic acid derivatives as IP antagonists | HOFFMANN LA ROCHE (CH) | 2003-05-14 | — | — | CN | disclosed |
| EP-1265853-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2001-12-27 | — | — | US | disclosed |
| WO-2001068591-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | AGTR1, AGTR2, PTGIR | SMN1; SMN2 4382/4885KMT2A 4027/4885MEN1 4055/4885 |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | SMN1; SMN2 4598/4885KMT2A 4130/4885MEN1 2412/4885 |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | SMN1; SMN2 4666/4885KMT2A 4182/4885MEN1 2555/4885 |
| US-20200361947-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | SMN1; SMN2 972/4885KMT2A 3587/4885MEN1 376/4885 |
| US-20050277628-A1 | Substituted thiophene carboxamides | OTC, SLC22A8, DDC | SMN1; SMN2 1529/4885KMT2A 1712/4885MEN1 2017/4885 |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | SMN1; SMN2 2205/4885KMT2A 4669/4885MEN1 1427/4885 |
| US-11591341-B2 | Bicyclic and tricyclic compounds | SLC10A1, PKD1, CYP11B2 | SMN1; SMN2 972/4885KMT2A 3587/4885MEN1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.